UAB Women & Infants Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Kenneth H
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Active, not recruiting
3
641
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
05/25
05/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
NCT05975840: Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Completed
1/2
518
US
FLU Q-PAN H5N8 Formulation 1, AS03B, AS03A, FLU Q-PAN H5N8 Formulation 2
GlaxoSmithKline
Influenza, Human
12/23
05/24

Download Options